摘要
Kirsten大鼠肉瘤病毒癌基因(Kirsten rat sarcoma viral oncogene,KRAS)突变是多种肿瘤中最常见的致癌因素之一,会导致KRAS的持续活化,进而促使细胞增殖癌变。多年来针对KRAS基因突变的靶向药物一直是研究的热点,但至今仍未能研发出有效针对KRAS基因突变的临床药物。目前靶向KRAS的研究主要通过直接抑制突变的KRAS基因、改变膜定位、靶向KRAS效应信号通路及抑制KRAS突变协同致死基因等机制。本文即对KRAS基因突变肿瘤靶向治疗药物的研究进展进行简要综述。
Kirsten rat sarcoma viral oncogene(KRAS) mutation is one of the most common carcinogenic factors in a variety of tumors,which leads to the continuous activation of KRAS,while it in turn promotes cell proliferation and drives tumorigenesis.Although the exploration of targeted drugs targeting KRAS gene mutations has been a hot research topic for decades,it has not yet been developed to discover clinically effective drugs for KRAS gene mutations.Currently,the mechanisms of targeted therapy for KRAS gene mutation are mainly inhibiting the mutated KRAS genes directly,changing the KRAS membrane localization,inhibiting KRAS signaling pathways,and inhibiting KRAS mutant synergistic lethal genes.Here,we briefly review the progress of pharmacological strategies targeting KRAS mutated cancers.
作者
卞赟艺(综述)
杨晓冬
詹成
姚光宇
毕国澍
范虹(审校)
BIAN Yun-yi;YANG Xiao-dong;ZHAN Cheng;YAO Guang-yu;BI Guo-shu;FAN Hong(Department of Thoracic Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2020年第3期439-447,455,共10页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金(81672268)
上海市自然科学基金(17ZR1405200)。
